The global benign prostatic hyperplasia (BPH) treatment market is witnessing significant growth due to various factors such as the increasing prevalence of BPH, advancements in treatment options, and the growing aging population. Benign prostatic hyperplasia, also known as enlarged prostate, is a common condition among older men that causes urinary symptoms such as frequent urination, weak urine flow, and difficulty in emptying the bladder. The market for BPH treatment is driven by the need for effective management of these symptoms and improving the quality of life for affected individuals.
The industry overview of the BPH treatment market showcases a positive growth trajectory. The global Benign Prostatic Hyperplasia (BPH) treatment market size was USD 11.50 Billion in 2022 and is expected to register a steady revenue CAGR of 5.3% during the forecast period, according to the latest analysis by Emergen Research. This growth can be attributed to the rising prevalence of BPH, increasing awareness about available treatment options, and technological advancements in the field of urology.
Several drivers are fueling the growth of the BPH treatment market. Firstly, the increasing aging population is a major driver. As men age, the risk of developing BPH increases, leading to a higher demand for treatment options. Additionally, advancements in treatment options, such as minimally invasive procedures like laser therapy and transurethral microwave therapy, are driving market growth. These procedures offer effective symptom relief with fewer complications and shorter recovery times compared to traditional surgical interventions.
However, the BPH treatment market also faces certain restraints. One of the key challenges is the high cost associated with some treatment options. Advanced procedures and technologies may be expensive, limiting their adoption in certain regions or among economically disadvantaged populations. Moreover, the availability of alternative treatment options, such as medication therapy, can also impact the market growth of surgical interventions.
Government organizations play a crucial role in monitoring and regulating the BPH treatment market. For instance, the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides statistics and information on BPH. According to the NIDDK, BPH affects approximately 50% of men between the ages of 51 and 60, and up to 90% of men over the age of 80. These statistics highlight the significant burden of BPH and the need for effective treatment options.
In terms of recent product launches, several top companies have introduced innovative solutions for BPH treatment. For example, in 2021, Boston Scientific launched the Rezūm System, a minimally invasive procedure that uses water vapor therapy to treat BPH. This product launch demonstrates Boston Scientific’s commitment to providing effective and less invasive treatment options for BPH patients. Another notable product launch is the UroLift System by Teleflex, which offers a minimally invasive approach to relieve urinary symptoms associated with BPH.
Factors influencing the growth of the Benign Prostatic Hyperplasia Treatment market and impacting the growth of the industry are studied extensively in the report. The report considers the COVID-19 pandemic as one of the key influencing factors of the Benign Prostatic Hyperplasia Treatment market. The report discusses in detail the positive and negative impact of the pandemic on the Benign Prostatic Hyperplasia Treatment industry. The supply chain disruptions and economic volatility have altered the dynamics of the Benign Prostatic Hyperplasia Treatment industry. The report explores the effects of the pandemic on the market and its key segments and regions. It also offers a forecast estimation of the market growth in a post-COVID-19 scenario.
Click the link to get a Free Sample Copy of the Report: @https://www.emergenresearch.com/request-sample/1971
Competitive Outlook: The leading companies operating in the Benign Prostatic Hyperplasia Treatment market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Top Companies Operating in the Benign Prostatic Hyperplasia Treatment Market and Profiled in the Report are:
AbbeVie Inc., Abbott, Boston Scientific Corporation, Teleflex Incorporated., Merck & Co. , Urologix, LLC., Allium Ltd., Boehringer Ingelheim International GmbH., Olympus Corporation, and Alembic Pharmaceuticals Limited
Objectives of the Report:
Study of the global Benign Prostatic Hyperplasia Treatment market size by key regions, types, and applications with reference to historical data (2017-2018) and forecast (2020-2027)
Industrial structure analysis of the Benign Prostatic Hyperplasia Treatment market by identification of various sub-segments
Extensive analysis of key market players along with their SWOT analysis
Competitive landscape benchmarking
Analysis of Benign Prostatic Hyperplasia Treatment market based on growth trends, futuristic outlook, and contribution to the total growth of the market
Analysis of drivers, constraints, opportunities, challenges, and risks in the global Benign Prostatic Hyperplasia Treatment market
Comprehensive analysis of competitive developments such as expansions, agreements, new product launches, and other strategic alliances
Enquire for customization in Report @:https://www.emergenresearch.com/request-for-customization/1971
Segments Covered in this report are:
-
Treatment Type Outlook (Revenue, USD Billion; 2019-2032)
- Mono Drug Therapy
- Combination Drug Therapy
-
Therapy Type Outlook (Revenue, USD Billion; 2019-2032)
- Drug Type
- Minimally Invasive Surgeries
- Laser therapy
- Others
-
Regional Outlook (Revenue, USD Billion; 2019–2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
- North America
Regional Segmentation:
North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Browse Detailed Research report @https://www.emergenresearch.com/industry-report/benign-prostatic-hyperplasia-treatment-market
Thank you for reading our report. For further queries regarding the report or customization options, please connect with us. Our team will ensure you get a report well-suited to your needs.
Look More Related Reports By Emergen Research
- Benign Prostatic Hyperplasia Treatment Market Size
- Benign Prostatic Hyperplasia Treatment Market Share
- Benign Prostatic Hyperplasia Treatment Market Trends
- Benign Prostatic Hyperplasia Treatment Regional Market Demand
- Benign Prostatic Hyperplasia Treatment Market Analysis
- Benign Prostatic Hyperplasia Treatment Market Top Companies
- Benign Prostatic Hyperplasia Treatment Market News
- Benign Prostatic Hyperplasia Treatment Market Executive Summary
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: http://www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services